/ABUS

Arbutus Biopharma Corp

ABUS

$5.12USD↑+0.00%+0.00 today

MARKET CAP

1.0B

P/E (TTM)

6.2x

FWD P/E

—

DAY RANGE

$5 – $5

52W RANGE

$4

$5

AI Summary

Stalk

Buy NowMedium

ABUS remains in a Stage 2 advance with price consolidating under recent highs while holding above rising EMAs. Neutral momentum indicators and tapering volume suggest continuation potential on shallow pullbacks. Execution near the rising 20-day EMA offers a favorable entry for the next leg higher, supported by the medium-term bullish trend. Resistance at the 52-week high zone may cap gains if not overcome on expanding volume.

↑Phase IIa data reveal 33%–67% undetectable HBsAg rates
↑$131M cash secures runway through Q4 2026 vs $63–67M burn
↓Projected $63–67M cash burn in 2024 risks runway

Full analysis →

Buying

4

institutions

Selling

5

institutions

New Positions

1

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	BUY	13.77 M	66.08 M	+799.12 K	+13.2%	0.00%
WP Woodline Partners LP Q2 2026	SELL	2.28 M	10.95 M	+-1.74 M	-39.5%	0.03%
AC Adar1 Capital Management, LLC Q2 2026	SELL	1.27 M	6.09 M	+-1.87 M	-56.8%	0.28%
MG Man Group Plc Q2 2026	BUYNEW	473.47 K	2.27 M	+473.47 K	+0.0%	0.00%
CA Citadel Advisors LLC Q2 2026	SELL	404.70 K	1.94 M	+-380.54 K	-45.0%	0.00%
JC Jpmorgan Chase & Co Q2 2026	BUY	98.22 K	459.69 K	+11.18 K	+22.8%	0.00%
AC Aqr Capital Management LLC Q2 2026	BUY	31.74 K	152.36 K	+7.92 K	+42.1%	0.00%
MM Millennium Management LLC Q2 2026	SELL	0.00	0.00	+-642.45 K	-100.0%	0.00%
BA Balyasny Asset Management L.P. Q2 2026	SELL	0.00	0.00	+-125.52 K	-100.0%	0.00%